“We are very pleased to be working together clobetasol topical and look forward to our continued relationship.” About SurModics, Inc. Finally, SurModics will be the paid development partner for PR Pharmaceuticals’ proprietary product called InsuLAR(TM), a once-a-week sustained release formulation of basal insulin for the diabetes marketplace. Anticipated Acquisition Benefits — Broadens SurModics’ proprietary technology portfolio in systemic drug delivery, including protein delivery — Enables delivery of injectable microparticles through smaller gauge needles — Expands SurModics’ customer base to incorporate several new pharmaceutical and biotech companies — Immediately adds new clobetasol topical sources of revenue and is expected to be accretive to SurModics fiscal 2009 earnings “The proprietary technologies and existing business we are acquiring from PR Pharmaceuticals are a perfect fit for SurModics,” said Cullan Skye, president and CEO of SurModics. A broader toolkit for protein mexico online pharmacy delivery and the ability to use smaller gauge needles for microparticle injections make an even more compelling offering for both current and future SurModics customers. PR Pharmaceuticals (PRP) is a biopharmaceutical company herb developing bioactive compounds in injectable sustained-release technologies.
In addition to the intellectual property being acquired, SurModics will be assuming responsibility for several customer-paid development projects currently in progress with pharmaceutical and biotechnology companies, including Jerini Ophthalmic. Second, the transaction will significantly advance the development of InsuLAR. SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Core offerings include. The acquisition is expected to be accretive to SurModics’ fiscal 2009 earnings, excluding any one-time charges related to the acquisition. SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery coral spring drug store projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations. “In particular, the ability to use smaller gauge needles for injections supplements for weight loss is of significant interest to customers in ophthalmology and several other clinical areas.
Drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. These reports are available in the Investors section of our website at and at the SEC website at. The company has developed significant intellectual property in manufacturing and formulation technologies for the encapsulation of large molecules such as proteins and peptides as well as classic small molecules into biodegradable microparticles. Adamis, M.D., president and CEO of Jerini Ophthalmic, Inc. Current efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. Statements mupirocin topical cream that are not historical or current facts, including statements about beliefs and expectations, such as the statement that the acquisition is expected to be accretive, excluding one-time charges, or the statement that the new technologies poise SurModics to drive customer programs and long-term revenue, are forward-looking statements.
For more information, please visit. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.. Forward-looking statements involve inherent risks and uncertainties, and important factors could can you get pregnant ortho evra cause actual results to differ materially from those anticipated, including the following. Also, the use of smaller needles is an advantage in many other applications requiring subcutaneous or intra-muscular injections, and in particular where patient self-administration is desired.
The use of smaller diameter needles for microparticle injection is particularly relevant in ophthalmology applications. The market for injectable basal insulin is estimated at best antidepressants approximately $4 billion worldwide. “The proprietary technologies complement and enhance the existing portfolio of drug delivery capabilities available from SurModics and Brookwood. Tipton, Ph.D., vice president of SurModics and president of Brookwood. “We are pleased to consummate this avalide erythromycin important transaction, and look forward to a long longs drugstore burien and successful association with SurModics,” said Towney R. In addition, partnering with PR Pharmaceuticals on the development of InsuLAR adds another promising development program in diabetes to our broad portfolio of customer programs. Today, PR Pharmaceuticals is already levocetirizine a customer of Brookwood for biodegradable polymer, which it uses in support of current development programs. We look forward to aiding PR Pharmaceuticals in the manufacturing scale-up and in the production of both clinical trial materials and final product for InsuLAR.” “The combined drug delivery expertise of SurModics, Brookwood, and PR Pharmaceuticals is exceptional,” said Anthony P.
SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located yasmin birth control in Birmingham, Alabama. Howe, chairman and CEO of PR Pharmaceuticals. Safe Harbor for Forward Looking Statements This contains forward-looking statements. While our immediate focus is commercialization of InsuLAR, we drug store anticipate working with SurModics on other collaborative programs in the future.” “Brookwood Pharmaceuticals slots casino free gains several attractive assets by vir of this transaction, which strengthens our portfolio of drug delivery technologies and will greatly benefit our customer development programs,” said Hinze J.
SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the successful achievement of certain milestones. Collaboration with the technical team and the cGMP manufacturing infrastructure at Brookwood will help ensure successful development and commercialization of InsuLAR as well as provide for a smooth transition for current PR Pharmaceuticals customers. “First, we along with drug testing kits Brookwood are committed to providing a smooth transition for current PR Pharmaceuticals customers to Brookwood. The multiple customer development programs we are assuming free prescription drugs in this transaction are a strong fit with the diversified portfolio of customer projects at Brookwood and will further leverage the investment we are making in cGMP manufacturing facilities in Birmingham. The content of SurModics’ website is not part of this release or part of any filings the company makes with the SEC. Third, continuation by SurModics of the multiple customer development programs allows PR Pharmaceuticals to focus on developing our own internal programs, products and technologies. For more information about the company, manali holiday apartment visit. (1) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies may adversely affect our business operations, our ability to realize the full potential of our pipeline, and the company’s ability to achieve our fiscal 2008 office the indiana state chemist corporate goals; (2) costs or difficulties relating to the integration of the businesses of Brookwood Pharmaceuticals, BioFX Laboratories, and the drug delivery assets and collaborative projects acquired from PR Pharmaceuticals, Inc., with SurModics’ business may be greater than expected and may adversely affect the company’s results of bracelet operations and financial condition; (3) developments in the regulatory environment, as well as market and economic conditions, may adversely affect our business operations and profitability; and (4) other factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form chemist prescription drugs without prescription eduard buchner 10-K for the fiscal year ended , and updated in our subsequent reports filed with the SEC.
Proteins and other large molecule therapeutics are of strategic interest to many biotechnology and pharmaceutical companies, but pose significant challenges for drug delivery. PRP is applying compelling and patented technology to focus its development efforts in rapidly moving InsuLAR, manali holiday apartment its long-acting basal insulin, into clinical trials. Further, with the addition of these new technologies, SurModics is poised to drive customer programs and long-term revenue even more effectively.” The proprietary technologies acquired from PR Pharmaceuticals have broad applicability and address key needs, enabling the delivery of injectable drugs, including proteins, using biodegradable microparticles through smaller diameter needles compared to competing technologies. The PR Pharmaceuticals technologies will complement those of SurModics no prescription pharmacy sites and its Brookwood Pharmaceuticals business unit and broaden the overall technology portfolio for the benefit of current and future customer projects. About PR Pharmaceuticals, Inc. Is a leading provider of surface modification and drug delivery technologies to the healthcare industry.